Form 4 for DNA Ginkgo Bioworks Holdings, Inc.
Accepted 2022-03-14 00:00:00 ET · period of report 2022-03-11 · accession 0000899243-22-010985 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-14 | 2022-03-11 | DNA | Sankar Shyam | Dir | A - Grant | $0.00 | +1.03M | 1.26M | +438% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-03-11 | A | A | 1,026,405 | $0.00 | 1,260,953 | D | — | — | (F1) The reporting person was previously granted awards of restricted stock units covering Class A Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 11, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 928,244 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class A Common Stock. The remaining restricted stock units will continue to vest in accordance with the terms of the award. |